{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T15:00:35Z","timestamp":1780671635868,"version":"3.54.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Australian Research Council Discovery","award":["DP120101963"],"award-info":[{"award-number":["DP120101963"]}]},{"name":"Victorian Government Operational Infrastructure Support Program"}],"content-domain":{"domain":["ijaaonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.ijantimicag.2013.08.001","type":"journal-article","created":{"date-parts":[[2013,9,7]],"date-time":"2013-09-07T14:15:32Z","timestamp":1378563332000},"page":"537-543","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Rapid systemic and local treatments with the antibacterial peptide dimer A3-APO and its monomeric metabolite eliminate bacteria and reduce inflammation in intradermal lesions infected with Propionibacterium acnes and meticillin-resistant Staphylococcus aureus"],"prefix":"10.1016","volume":"42","author":[{"given":"Eszter","family":"Ostorhazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Voros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Nemes-Nikodem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palma","family":"Sillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balazs","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Wade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Laszlo","family":"Otvos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2013.08.001_bib0005","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1128\/AAC.06304-11","article-title":"Efficacy of OH-CATH30 and its analogs against drug-resistant bacteria in vitro and in mouse models","volume":"56","author":"Li","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.08.001_bib0010","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.mib.2004.08.013","article-title":"Taking inventory: antibacterial agents currently at or beyond Phase 1","volume":"7","author":"Bush","year":"2004","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.ijantimicag.2013.08.001_bib0015","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.coph.2006.04.006","article-title":"Antibacterial peptides for therapeutic use: obstacles and realistic outlook","volume":"6","author":"Marr","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2013.08.001_bib0020","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1021\/cb300063v","article-title":"Api88 is a novel antibacterial designer peptide to treat systemic infections with multidrug-resistant Gram-negative pathogens","volume":"7","author":"Czihal","year":"2012","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.ijantimicag.2013.08.001_bib0025","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.4049\/jimmunol.1102777","article-title":"The human lactoferrin-derived peptide hLF1-11 exerts immunomodulatory effects by specific inhibition of myeloperoxidase activity","volume":"188","author":"van der Does","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.ijantimicag.2013.08.001_bib0030","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1128\/AAC.00267-11","article-title":"Humanized \u03b8-defensins (retrocyclins) enhance macrophage performance and protect mice from experimental anthrax infections","volume":"55","author":"Welkos","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2013.08.001_bib0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2172-13-61","article-title":"New perspectives for natural antimicrobial peptides: application as anti-inflammatory drugs in a murine model","volume":"13","author":"Capparelli","year":"2012","journal-title":"BMC Immunol"},{"key":"10.1016\/j.ijantimicag.2013.08.001_bib0040","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1110\/ps.034330.108","article-title":"Alternative stabilities of a proline-rich antibacterial peptide in vitro and in vivo","volume":"17","author":"Noto","year":"2008","journal-title":"Protein Sci"},{"key":"10.1016\/j.ijantimicag.2013.08.001_bib0045","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ijantimicag.2009.10.015","article-title":"The designer proline-rich antibacterial peptide A3-APO is effective against systemic Escherichia coli infections in different mouse models","volume":"35","author":"Szabo","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2013.08.001_bib0050","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/bip.21443","article-title":"Intramuscularly administered peptide A3-APO is effective against carbapenem-resistant Acinetobacter baumannii in mouse models of systemic infections","volume":"96","author":"Ostorhazi","year":"2011","journal-title":"Biopolymers"},{"key":"10.1016\/j.ijantimicag.2013.08.001_bib0055","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1093\/jac\/dkq337","article-title":"Preclinical advantages of intramuscularly administered peptide A3-APO over existing therapies in Acinetobacter baumannii wound infections","volume":"65","author":"Ostorhazi","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2013.08.001_bib0060","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ijantimicag.2011.01.003","article-title":"Broad-spectrum antimicrobial efficacy of peptide A3-APO in mouse models of multidrug-resistant wound and lung infections cannot be explained by in vitro activity against the pathogens involved","volume":"37","author":"Ostorhazi","year":"2011","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl A","key":"10.1016\/j.ijantimicag.2013.08.001_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/39.suppl_1.1","article-title":"Gram-positive resistance: challenge for the development of new antibiotics","volume":"39","author":"Baquero","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2013.08.001_bib0070","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta9010","article-title":"Randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne","volume":"9","author":"Ozolins","year":"2005","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.ijantimicag.2013.08.001_bib0075","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/jac\/49.3.455","article-title":"In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone","volume":"49","author":"Yamakawa","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2013.08.001_bib0080","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.1021\/jm050347i","article-title":"Designer antibacterial peptides kill fluoroquinolone-resistant clinical isolates","volume":"48","author":"Otvos","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.ijantimicag.2013.08.001_bib0085","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1016\/j.vaccine.2011.02.036","article-title":"Passive immunoprotection targeting a secreted CAMP factor of Propionibacterium acnes as a novel immunotherapeutic for acne vulgaris","volume":"29","author":"Liu","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.ijantimicag.2013.08.001_bib0090","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1128\/JCM.00722-06","article-title":"Susceptibilities of Propionibacterium acnes ophthalmic isolates to ertapenem, meropenem and cefepime","volume":"44","author":"Shames","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2013.08.001_bib0095","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jpag.2007.07.004","article-title":"English JC III. Adolescent female acne: etiology and management","volume":"21","author":"Olutunmbi","year":"2008","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"10.1016\/j.ijantimicag.2013.08.001_bib0100","doi-asserted-by":"crossref","first-page":"e22120","DOI":"10.1371\/journal.pone.0022120","article-title":"Cathelicidin-BF, a snake cathelicidin-derived antimicrobial peptide, could be an excellent therapeutic agent for acne vulgaris","volume":"7","author":"Wang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2013.08.001_bib0105","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1074\/jbc.M406968200","article-title":"Distinct roles for the \u03b1 and \u03b2 subunits in the functions of integrin \u03b1M\u03b22","volume":"280","author":"Solovjov","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijantimicag.2013.08.001_bib0110","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0022-1759(94)90005-1","article-title":"Markers of mouse macrophage development detected by monoclonal antibodies","volume":"174","author":"Leenen","year":"1994","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.ijantimicag.2013.08.001_bib0115","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1189\/jlb.0704380","article-title":"Impact of LL-37 on anti-infective immunity","volume":"77","author":"Bowdish","year":"2005","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.ijantimicag.2013.08.001_bib0120","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1067-1927.2004.012303.x","article-title":"HB-107, a nonbacteriostatic fragment of the antibacterial peptide cecropin B, accelerates murine wound repair","volume":"12","author":"Lee","year":"2004","journal-title":"Wound Repair Regen"},{"key":"10.1016\/j.ijantimicag.2013.08.001_bib0125","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1128\/CVI.00291-12","article-title":"Identification of synthetic host defense peptide mimics that exert dual antimicrobial and anti-inflammatory activities","volume":"19","author":"Som","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.ijantimicag.2013.08.001_bib0130","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.4049\/jimmunol.0901813","article-title":"Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment","volume":"184","author":"Nijnik","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.ijantimicag.2013.08.001_bib0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1574-6968.2006.00156.x","article-title":"Anti-inflammatory activity of cationic peptides: application to the treatment of acne vulgaris","volume":"257","author":"Guarna","year":"2006","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.ijantimicag.2013.08.001_bib0140","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.peptides.2012.02.010","article-title":"Peptides with antimicrobial and anti-inflammatory activities that have therapeutic potential for treatment of acne vulgaris","volume":"34","author":"Popovic","year":"2012","journal-title":"Peptides"},{"key":"10.1016\/j.ijantimicag.2013.08.001_bib0145","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10989-009-9176-1","article-title":"Induced resistance to the designer proline-rich antimicrobial peptide A3-APO does not involve changes in the intracellular target DnaK","volume":"15","author":"Cassone","year":"2009","journal-title":"Int J Pept Res Ther"},{"key":"10.1016\/j.ijantimicag.2013.08.001_bib0150","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1146\/annurev-pharmtox-010611-134535","article-title":"Emerging themes and therapeutic prospects for anti-infective peptides","volume":"52","author":"Yount","year":"2012","journal-title":"Annu Rev Pharmacol Toxicol"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857913002914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857913002914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,13]],"date-time":"2018-10-13T09:20:38Z","timestamp":1539422438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857913002914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0924857913002914"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.08.001","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapid systemic and local treatments with the antibacterial peptide dimer A3-APO and its monomeric metabolite eliminate bacteria and reduce inflammation in intradermal lesions infected with Propionibacterium acnes and meticillin-resistant Staphylococcus aureus","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2013.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}